Stockpile boost for Biota
Monday, 02 February, 2009
The UK Government has purchased over 10 million treatment courses of zanamivir, the flu antiviral developed by Biota and marketed by GlaxoSmithKline as Relenza.
The Government also bought an extra eight million courses of oseltamivir, the antiviral marketed as Tamiflu by Roche. Evidence is emerging of resistance to Tamiflu, the market-leading flu treatment.
The purchase means the UK now has enough antivirals stockpiled to treat 50 per cent of its population in the event of an epidemic.
In a statement, Biota said that while the financial terms of the contract have not been revealed, it represents a potential royalty to the Melbourne company of up to $18 million.
Last year, Biota dropped long-standing legal action against GSK for failing to market Relenza properly. The company said it had lost up to $400 million in potential royalties but eventually settled the case for $20 million.
The company is now in Phase III trials of a long-acting neuraminidase inhibitor, developed with partner Daiichi Sankyo, for human and bird flu.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
